ES2137635T3 - Composicion liquida estable que contiene urato oxidasa y composicion liofilizada para su preparacion. - Google Patents

Composicion liquida estable que contiene urato oxidasa y composicion liofilizada para su preparacion.

Info

Publication number
ES2137635T3
ES2137635T3 ES96400995T ES96400995T ES2137635T3 ES 2137635 T3 ES2137635 T3 ES 2137635T3 ES 96400995 T ES96400995 T ES 96400995T ES 96400995 T ES96400995 T ES 96400995T ES 2137635 T3 ES2137635 T3 ES 2137635T3
Authority
ES
Spain
Prior art keywords
preparation
urate oxidase
stable liquid
liquid composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96400995T
Other languages
English (en)
Inventor
Claude Aleman
Alain Bayol
Thierry Breul
Patrice Dupin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of ES2137635T3 publication Critical patent/ES2137635T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION LIQUIDA FARMACEUTICA ACEPTABLE, ESTABLE FISICAMENTE, QUE CONTIENE URATO OXIDASA, Y DE 0,1 MG/ML A 10 MG/ML DE POLOXAMER 188, EN MEDIO ACUOSO TAMPONADO. ESTA COMPOSICION PUEDE OBTENERSE POR DISOLUCION DE UN LIOFILIZADO EN UN SOLVENTE ACUOSO.
ES96400995T 1995-05-11 1996-05-09 Composicion liquida estable que contiene urato oxidasa y composicion liofilizada para su preparacion. Expired - Lifetime ES2137635T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9505606A FR2733914B1 (fr) 1995-05-11 1995-05-11 Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US08/644,163 US5811096A (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Publications (1)

Publication Number Publication Date
ES2137635T3 true ES2137635T3 (es) 1999-12-16

Family

ID=26231954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96400995T Expired - Lifetime ES2137635T3 (es) 1995-05-11 1996-05-09 Composicion liquida estable que contiene urato oxidasa y composicion liofilizada para su preparacion.

Country Status (24)

Country Link
US (1) US5811096A (es)
EP (1) EP0742013B1 (es)
JP (1) JP2950775B2 (es)
CN (1) CN1090972C (es)
AT (1) ATE183925T1 (es)
AU (1) AU710288B2 (es)
BR (1) BR1100337A (es)
CA (1) CA2175971C (es)
CZ (1) CZ290799B6 (es)
DE (1) DE69604009T2 (es)
DK (1) DK0742013T3 (es)
EA (1) EA000024B1 (es)
ES (1) ES2137635T3 (es)
FR (1) FR2733914B1 (es)
GR (1) GR3031896T3 (es)
HU (1) HU225147B1 (es)
IL (1) IL118171A (es)
NO (1) NO315261B1 (es)
NZ (1) NZ286554A (es)
PL (1) PL184135B1 (es)
SG (1) SG42355A1 (es)
SI (1) SI0742013T1 (es)
TW (1) TW420614B (es)
ZA (1) ZA963683B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006110761A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
CN1864744B (zh) * 2005-05-18 2010-09-29 杭州北斗生物技术有限公司 含有尿酸氧化酶的药用制剂
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
CN101622270B (zh) 2006-04-12 2014-01-01 萨文特医药公司 用阳离子表面活性剂纯化蛋白质的方法
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
US20190060241A1 (en) * 2016-04-13 2019-02-28 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
KR101744900B1 (ko) * 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
US3928137A (en) * 1971-10-20 1975-12-23 Mallinckrodt Inc Reagent formulation for uric acid assay
JPS51104807A (en) * 1975-03-12 1976-09-17 Hitachi Ltd Teepurekoodano ootoribaasuseigyokairo
JPS5417027A (en) * 1977-07-07 1979-02-08 Canon Inc Image forming system
DE3126759A1 (de) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JPS60224499A (ja) * 1984-04-23 1985-11-08 Toyobo Co Ltd 安定なウリカ−ゼ製剤
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JPH0243471A (ja) * 1988-08-03 1990-02-14 Iwataro Moriyama 立体駐車装置
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
CA2130357A1 (en) 1992-02-18 1993-08-19 Doron Friedman Dry compositions for preparing submicron emulsions

Also Published As

Publication number Publication date
NO961915D0 (no) 1996-05-10
DK0742013T3 (da) 2000-03-06
MX9601756A (es) 1997-07-31
EA199600024A2 (ru) 1996-12-30
HUP9601241A3 (en) 2000-06-28
EA000024B1 (ru) 1997-12-30
DE69604009D1 (de) 1999-10-07
IL118171A (en) 2000-08-31
ATE183925T1 (de) 1999-09-15
JPH0925242A (ja) 1997-01-28
SI0742013T1 (en) 1999-12-31
GR3031896T3 (en) 2000-02-29
AU710288B2 (en) 1999-09-16
IL118171A0 (en) 1996-09-12
EP0742013B1 (fr) 1999-09-01
EA199600024A3 (ru) 1997-03-31
EP0742013A1 (fr) 1996-11-13
CZ135096A3 (en) 1996-12-11
AU5213996A (en) 1996-11-21
HU225147B1 (en) 2006-07-28
US5811096A (en) 1998-09-22
NZ286554A (en) 1998-09-24
JP2950775B2 (ja) 1999-09-20
NO315261B1 (no) 2003-08-11
PL314147A1 (en) 1996-11-12
ZA963683B (en) 1997-11-10
HUP9601241A2 (en) 1997-04-28
TW420614B (en) 2001-02-01
CN1147961A (zh) 1997-04-23
CA2175971C (en) 2003-12-30
SG42355A1 (en) 1997-08-15
HU9601241D0 (en) 1996-07-29
CN1090972C (zh) 2002-09-18
DE69604009T2 (de) 2000-04-06
FR2733914B1 (fr) 1997-08-01
CZ290799B6 (cs) 2002-10-16
NO961915L (no) 1996-11-12
PL184135B1 (pl) 2002-09-30
CA2175971A1 (en) 1996-11-12
BR1100337A (pt) 2000-07-25
FR2733914A1 (fr) 1996-11-15

Similar Documents

Publication Publication Date Title
ES2137635T3 (es) Composicion liquida estable que contiene urato oxidasa y composicion liofilizada para su preparacion.
KR960037063A (ko) 인터페론 용액
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
ES2193515T3 (es) Composicion farmaceutica que comprende un compuesto triciclico con mejor estabilidad, absortividad y escaso potencial irritativo.
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
ES2145158T3 (es) Nueva formulacion de emulsion.
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
EE05072B1 (et) Farmatseutilised kompositsioonid limaskestale kandmiseks
PA8458101A1 (es) Formas de dosificacion farmaceuticas solidas
PL335575A1 (en) Hydrophilic two-component systems for use in administration of cyclosporine
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
BR9706537A (pt) Composição farmacêutica para administração por via oral
ES2148755T3 (es) Formulaciones que contienen leflunomida.
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
BR9913135A (pt) Formulação oral
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
BR9805875A (pt) Composições farmacêuticas de droloxifeno.
ES2124852T3 (es) Formulaciones de rapamicina para administracion oral.
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
BR0011864A (pt) Formulações farmacêuticas
AU4929400A (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
KR970073583A (ko) 탁속을 함유한 주사용 약제 조성물
BR0014058A (pt) Produto sólido, composição, solução aquosa de 4,4-dimetil-5a-colesta-8,14,24-triene-3(beta) -ol, e, dispositivo tendo uma concavidade
ATE263576T1 (de) Prostaglandine und benzylalcohol enthaltende lösung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 742013

Country of ref document: ES